STK10

Across TCGA pan-cancer cohorts, STK10 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of STK10’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where STK10 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types STK10 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where STK10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STK10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.829	<.001	12	view →
HNSC	Male	All	+0.574	<.001	11	view →
LUAD	Female	II,III,IV	−0.448	<.001	9	view →
COAD	Male	II,III,IV	+0.271	<.001	9	view →
LSCC	Male	II,III,IV	−0.397	<.001	7	view →
PDAC	Female	All	+0.588	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

STK10–CCRCC

Open the CCRCC breakdown →